Trial Profile
Initiation of insulin glargine 300 U/mL in type 2 diabetic patients after failure of pre-existing BOT treatment with any other basal insulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TOP-2
- Sponsors Sanofi-Aventis GmbH
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 01 Dec 2018 Results published in the Diabetes Therapy
- 05 Oct 2018 Results from German population(n=679) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes